Autolus Therapeutics plc Increase Decrease In Operating Lease Liability
Autolus Therapeutics plc (AUTL) reported Increase Decrease In Operating Lease Liability of $1.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Autolus Therapeutics plc increase decrease in operating lease liability for the quarter ending 2026-06-30 was $1.14M, a 89.13% decline year-over-year.
- Autolus Therapeutics plc increase decrease in operating lease liability for the quarter ending 2026-03-31 was $194.00K.
- Autolus Therapeutics plc increase decrease in operating lease liability for the quarter ending 2025-12-31 was $5.42M, a 46.05% increase year-over-year.
- Autolus Therapeutics plc increase decrease in operating lease liability for the quarter ending 2025-09-30 was $2.59M.
- Autolus Therapeutics plc increase decrease in operating lease liability for fiscal 2025 was $14.64M.
- Autolus Therapeutics plc increase decrease in operating lease liability for fiscal 2024 was -$369.00K.
- Autolus Therapeutics plc increase decrease in operating lease liability for fiscal 2023 was -$13.55M.
- Autolus Therapeutics plc increase decrease in operating lease liability for fiscal 2022 was -$4.69M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 3 month as first filed | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.33M 10-Q · filed 2026-08-11 | $6.75M derived: sum of 3 quarters · filed 2026-08-11 | $9.34M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $194.00K 10-Q · filed 2026-05-14 | $5.61M derived: sum of 2 quarters · filed 2026-05-14 | $8.20M derived: sum of 3 quarters · filed 2026-05-14 | $18.66M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $8.01M derived: sum of 2 quarters · filed 2026-03-27 | $18.47M derived: sum of 3 quarters · filed 2026-08-11 | $14.64M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $13.05M derived: sum of 2 quarters · filed 2026-08-11 | $9.23M 10-Q · filed 2025-11-12 | $12.94M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $10.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.63M 10-Q · filed 2026-08-11 | $10.34M derived: sum of 3 quarters · filed 2026-08-11 | $8.87M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$3.83M 10-Q · filed 2026-05-14 | $3.25M 10-Q · filed 2025-05-08 | -$117.00K derived: sum of 2 quarters · filed 2026-05-14 | -$1.59M derived: sum of 3 quarters · filed 2026-05-14 | -$3.01M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $2.23M derived: sum of 2 quarters · filed 2026-03-27 | $815.00K derived: sum of 3 quarters · filed 2026-03-27 | -$369.00K 10-K · filed 2026-03-27 | |||
| 2024-09-30 | -$1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.89M derived: sum of 2 quarters · filed 2025-11-12 | -$4.08M 10-Q · filed 2025-11-12 | -$5.67M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | -$1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$2.60M 10-Q · filed 2025-08-12 | -$4.19M derived: sum of 3 quarters · filed 2025-08-12 | -$9.36M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | -$1.18M 10-Q · filed 2025-05-08 | -$2.77M derived: sum of 2 quarters · filed 2025-05-08 | -$7.95M derived: sum of 3 quarters · filed 2025-05-08 | -$12.61M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | -$1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$6.76M derived: sum of 2 quarters · filed 2025-03-20 | -$11.43M derived: sum of 3 quarters · filed 2025-03-20 | -$13.55M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | -$5.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$9.84M derived: sum of 2 quarters · filed 2024-11-12 | -$11.96M 10-Q · filed 2024-11-12 | -$9.00M 6-K · filed 2023-11-02 | -$16.18M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$4.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.79M 10-Q · filed 2024-08-08 | -$11.01M derived: sum of 3 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$2.13M 10-Q · filed 2024-05-17 | -$6.34M derived: sum of 2 quarters · filed 2024-05-17 | |||||
| 2022-12-31 | -$4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$4.69M 10-K · filed 2024-03-21 | -$1.25M 20-F · filed 2023-03-07 | ||||
| 2022-09-30 | -$472.00K 10-Q · filed 2023-11-09 | ||||||
| 2021-12-31 | -$2.40M 10-K · filed 2024-03-21 | ||||||
| 2020-12-31 | $168.00K 20-F · filed 2023-03-07 | -$3.50M 20-F · filed 2022-03-10 | |||||
| 2019-12-31 | -$552.00K 20-F · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |